Author Correction: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.
Author Correction: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.
复制标题
作者更正：针对间日疟原虫和恶性疟原虫的肝脏阶段治疗评估的综合模型。
DOI：
10.1038/s41467-018-04817-1
复制
发表时间：
2018
影响因子：
16.6
通讯作者：
Rou
中科院分区：
文献类型：
--
作者：
Roth,Alison;Maher,StevenP;Conway,AmyJ;Ubalee,Ratawan;Chaumeau,Victor;Andolina,Chiara;Kaba,StephenA;Vantaux,Amélie;Bakowski,MalinaA;Thomson-Luque,Richard;Adapa,SwamyRakesh;Singh,Naresh;Barnes,SamanthaJ;Cooper,CaitlinA;Rou
Malaria liver stages represent an ideal therapeutic target with a bottleneck in parasite load and reduced clinical symptoms; however, current in vitro pre-erythrocytic (PE) models forPlasmodium vivaxandP.falciparumlack the efficiency necessary for rapid identification and effective evaluation of new vaccines and drugs, especially targeting late liver-stage development and hypnozoites. Herein we report the development of a 384-well plate culture system using commercially available materials, including cryopreserved primary human hepatocytes. Hepatocyte physiology is maintained for at least 30 days and supports development ofP.vivaxhypnozoites and complete maturation ofP.vivaxandP.falciparumschizonts. Our multimodal analysis in antimalarial therapeutic research identifies important PE inhibition mechanisms: immune antibodies against sporozoite surface proteins functionally inhibit liver stage development and ion homeostasis is essential for schizont and hypnozoite viability. This model can be implemented in laboratories in disease-endemic areas to accelerate vaccine and drug discovery research.
